You are here » Home » Companies » Company Overview » ERIS Lifesciences Ltd

ERIS Lifesciences Ltd.

BSE: 540596 Sector: Health care
NSE: ERIS ISIN Code: INE406M01024
BSE LIVE 15:43 | 13 Dec 781.95 -11.95
(-1.51%)
OPEN

799.00

HIGH

799.00

LOW

777.00

NSE 15:50 | 13 Dec 781.25 -16.75
(-2.10%)
OPEN

799.00

HIGH

800.10

LOW

776.00

OPEN 799.00
PREVIOUS CLOSE 793.90
VOLUME 5899
52-Week high 830.95
52-Week low 510.50
P/E 46.85
Mkt Cap.(Rs cr) 10,752
Buy Price 0.00
Buy Qty 0.00
Sell Price 781.95
Sell Qty 13.00
OPEN 799.00
CLOSE 793.90
VOLUME 5899
52-Week high 830.95
52-Week low 510.50
P/E 46.85
Mkt Cap.(Rs cr) 10,752
Buy Price 0.00
Buy Qty 0.00
Sell Price 781.95
Sell Qty 13.00

ERIS Lifesciences Ltd. (ERIS) - Chairman Speech

Company chairman speech

Dear Shareholders

It is indeed a pleasure to present our maiden annual report since our listing on thestock exchange in June 2017. This marks an important milestone in our successful journeyover the past 10 years and I am humbled by the overwhelming response shown by theshareholders. The IPO worth INR 17411 million was one of the largest ever witnessed inthe pharmaceutical space. This goes on to prove the immense faith that the financialmarkets have in our business model.

Eris is engaged in the business of manufacturing and marketing branded formulations. Wecater to specific therapeutic areas in the chronic and specialty acute categories. Thesecategories are primarily related to lifestyle disorders and are treated by superspecialistand specialist doctors. These diseases have been on the rise in India due to modern-daysedentary lifestyle unhealthy eating habits and rising work-related stress. The segmentsfocussed by our Company are amongst the fastest growing segments of the industry.

Driven by this unique positioning in the market and focus on high growth therapeuticsegments along with strong portfolio of brands we have emerged as the fastest growingcompany in the chronic category of the IPM*.

Our revenue for this year increased by 21.5% to INR 7250 million despite thetemporary disruption due to demonstration. The therapeutic areas of cardiovascularanti-diabetics vitamins and gastroenterology together accounted for nearly 85% of therevenues.The contribution of revenues from our top 10 and top 25 mother brands at 72.5%and 92.2% respectively was higher than the average of top 25 companies in IPM at 48% and69% respectively. This indicates the robustness of products in our top mother brands. Inaddition to this 73% and 25% of our FY 2016-17 revenues came from products in the growthand mature phases of lifecycle of their representative pharmaceutical moleculesrespectively indicating the newness of our products and significant growth opportunitythey provideforthefuture. Our per man per month productivity is INR 4 Lakh. We aspire toachieve industry leading productivity. Our prescription ranking across most of the motherbrands have also witnessed improvement over the years.

During the year we also undertook strategic acquisitions which include:

Acquired 75.48% stake in Kinedex Healthcare which caters to mobility-relateddisorders. This shall facilitate us to diversify our product offerings.

Acquired trademarks of 40 brands from Amay Pharma to strengthen portfolio in thecardiovascular and anti-diabetics therapeutic segments.

We entered into agreement with India Medtronic for distribution marketing andpromotion of the ‘i-Port Advance' injection port India Medtronic is a wholly-ownedsubsidiary of Medtronic Plc. one of the largest medical technology company in the word.‘i-Port Advance' injection port requires lesser injections than the standard insulindelivery methods.

An increase in lifestyle disorders has increased the prevalence of chronic diseases. Asper International Diabetes Federation (IDF) India had the second highest number ofdiabetics in the world in FY 2015 with 69.2 million adults living with diabetes. Thisnumber is likely to touch 87 million by FY 2030 as per IDF estimates. India has amongstthe highest rates of cardiovascular disease (CVD) globally.** As per WHOCardivascular diseases contribute to 26% of deaths in India. The major challenge for ourcountry would be to effectively manage the burden of chronic diseases. We will continue inour endeavour to provide better healthcare solutions via superior products and patientcare initiatives to enable early detection. Recently the government has also decided todouble post graduate medical seats in the next 5 years. This will significantly increasethe number of superspecialist doctors helping to bridge the huge gap in doctor-patientratio that currently exists in our country.

In addition to this we are actively exploring new acquisition and in-licensingopportunities to further strengthen our product offerings and diversify to newertherapeutic areas. We intend to consolidate positions in our existing product areas assignificant opportunities still exist. We have undertaken patient care initiatives such as‘pathfinder' through which we offer access to various diagnostic tools for betterclinical outcomes. ABPM on call and CGM on call are some of the tools made accessibleunder this initiative.

With enough growth opportunities and right steps taken by us we expect to continuewith our present growth momentum and maximise shareholder value. I also take thisopportunity to thank all our people who have partnered with us in taking Eris Lifesciencesto newer heights and making it a brand of repute in just ten years of its existence.

Warm regards

Amit Bakshi